Media reports indicate Merck is in talks to acquire Revolution Medicines for an offer in the $28–32 billion range, joining other potential bidders. Revolution’s late‑stage RAS pathway assets, including daraxonrasib with a fast‑track review voucher, make the company a strategic target as large pharma firms seek post‑Keytruda oncology entrants. The story remains fluid; sources caution any agreement could take weeks and other bidders remain possible.